# Corticosteroid Therapy in Feline Diseases: Special Considerations


## Key Takeaways

- Prednisolone is the preferred oral glucocorticoid in cats due to their reduced hepatic capacity to convert prednisone to its active metabolite, prednisolone.
- The dose-response relationship for corticosteroids in cats exhibits an inverted-U pattern, meaning moderate doses provide maximal benefit, while very high doses can diminish efficacy and increase adverse effects.
- Common adverse effects in cats include weight loss, muscle wasting, iatrogenic hyperadrenocorticism, diabetes mellitus, and skin fragility, necessitating careful monitoring of blood glucose, blood pressure, and body condition.
- Gradual tapering of corticosteroids is mandatory after more than two weeks of therapy to allow for the recovery of the hypothalamic-pituitary-adrenal (HPA) axis and prevent hypoadrenocortical crisis.
- Monitoring for cats on maintenance corticosteroid therapy should include blood glucose and fructosamine, blood pressure, urinalysis with culture, and serum creatinine/SDMA, with rechecks typically every 1 to 3 months.
- Corticosteroid therapy in cats can precipitate or exacerbate concurrent conditions such as diabetes mellitus and congestive heart failure, requiring a thorough pretreatment assessment and risk-benefit analysis.

---

Cats present a distinct pharmacological profile for corticosteroid therapy that differs meaningfully from dogs and other companion animals. This article addresses the practicing veterinarian managing feline patients who require glucocorticoid treatment for inflammatory, immune-mediated, neoplastic, or endocrine conditions. It covers receptor physiology, drug selection, dosing strategy, adverse effect recognition, and monitoring frameworks specific to cats. The content assumes working familiarity with corticosteroid pharmacology and focuses on where feline responses diverge from expectations built on canine or human experience.

The clinical questions this article answers are practical: Which corticosteroid should be chosen for a given feline disease? How should induction and maintenance dosing be structured? What adverse effects warrant monitoring, and at what intervals? How does chronic therapy alter the approach to concurrent illness, surgery, or vaccination? Where the evidence base in cats is thin, that limitation is stated directly, and the reader is directed to consult current formularies and product labeling for specific dose figures.

## At a Glance

| Parameter | Feline Consideration |
|---|---|
| Primary receptor targets | Glucocorticoid receptor (Type II) mediates most therapeutic and adverse effects, mineralocorticoid receptor (Type I) occupancy becomes relevant at high doses |
| Drug selection | Prednisolone preferred over prednisone in cats due to reduced hepatic conversion capacity |
| Dose-response relationship | Inverted-U relationship between corticosteroid dose and physiologic effect, documented in animal models |
| Induction strategy | Higher frequency dosing initially, then taper based on disease response and adverse effect tolerance |
| Common adverse effects | Weight loss, muscle wasting, diabetes mellitus, skin fragility, behavioral changes |
| Monitoring interval | Recheck at 2 to 4 weeks after induction, then every 1 to 3 months during maintenance |
| Concurrent disease risk | Diabetes mellitus and heart disease alter risk-benefit calculus substantially |
| Withdrawal requirement | Gradual taper mandatory after more than 2 weeks of therapy to permit HPA axis recovery |

## Glucocorticoid Receptor Physiology and Feline Specificity

Corticosteroids exert their effects through intracellular receptors that function as ligand-activated transcription factors. Two receptor types mediate these actions. Type I, the mineralocorticoid receptor, binds cortisol with high affinity and is largely occupied at basal circulating concentrations. Type II, the glucocorticoid receptor, binds cortisol with lower affinity and becomes progressively occupied as corticosteroid concentrations rise above baseline. The therapeutic and adverse effects of exogenous corticosteroid administration are mediated predominantly through Type II receptor occupancy, with Type I recruitment occurring at supraphysiologic doses. This two-receptor model helps explain why low-dose and high-dose therapy produce qualitatively different outcomes, a relationship that has been characterized in both animal and human studies of corticosteroid effects on cognition and other systems [Lupien and McEwen, integration of animal and human model studies](https://pubmed.ncbi.nlm.nih.gov/9233540/).

The sodium pump, Na(+)-K(+)-ATPase, represents a downstream effector of corticosteroid signaling that illustrates the breadth of corticosteroid influence beyond immune modulation. This membrane-bound enzyme maintains the sodium and potassium gradients across plasma membranes, and its activity is regulated by corticosteroids among other hormones. The regulation is tissue-specific and involves multiple mechanisms, including substrate availability, membrane-associated components, and intracellular signaling pathways [Therien and Blostein, mechanisms of sodium pump regulation](https://pubmed.ncbi.nlm.nih.gov/10942705/). For the feline clinician, this physiology explains why corticosteroid therapy can perturb fluid balance, potassium homeostasis, and cardiovascular function, particularly in patients with preexisting cardiac or renal disease.

## Pharmacokinetic Differences in Cats

Cats metabolize corticosteroids differently from dogs in ways that affect drug selection. Prednisone requires hepatic conversion to prednisolone via 11-beta-hydroxysteroid dehydrogenase to become active. Cats have reduced capacity for this conversion compared to dogs, making prednisolone the more reliable choice for oral therapy. This difference is clinically meaningful for induction dosing, where delayed activation of prednisone can blunt the initial response or create dosing uncertainty.

The feline liver also handles corticosteroid clearance with notable individual variation. Obese cats, cats with hepatic disease, and geriatric patients may show prolonged drug half-life, increasing the risk of cumulative adverse effects. Conversely, hyperthyroid cats may clear corticosteroids more rapidly. These variables argue for individualizing dose intervals instead of applying fixed schedules, and for reassessing the dose at each recheck examination.

## The Inverted-U Dose Response

The relationship between corticosteroid dose and therapeutic effect is not linear. Experimental studies in animals and humans demonstrate an inverted-U shape, where low doses produce minimal effect, moderate doses produce maximal benefit, and high doses produce diminished benefit with increased adverse effects [Lupien and McEwen, integration of animal and human model studies](https://pubmed.ncbi.nlm.nih.gov/9233540/). This pattern has direct clinical implications for feline therapy. Pushing the dose higher in a cat that is not responding may worsen the outcome instead of improve it. When a cat fails to respond to an adequate induction dose, the clinician should question the diagnosis, consider alternative or adjunctive therapy, and reassess instead of simply escalate.

The inverted-U relationship also informs the taper schedule. Rapid reduction from a high dose can precipitate disease flare while gradual reduction allows the clinician to identify the minimum effective dose for maintenance. The goal of chronic therapy is to find the lowest dose that controls the disease process, not to eliminate all signs of inflammation.

## Translational Limitations in Corticosteroid Research

Much of the foundational research on corticosteroid mechanisms derives from rodent models and human clinical trials. Systematic comparison of animal experiments with clinical trial outcomes reveals that treatment effects observed in animal models do not always translate to human patients, and the direction of effect can even reverse [Perel et al., comparison of treatment effects between animal experiments and clinical trials](https://pubmed.ncbi.nlm.nih.gov/17175568/). Corticosteroids for head injury, for example, showed benefit in animal models but no benefit and possible harm in clinical trials. This discordance cautions against assuming that feline responses will mirror those predicted by other species.

For feline-specific corticosteroid use, the evidence base is largely extrapolated from canine medicine, human medicine, and clinical experience instead of controlled feline trials. Conditions such as feline inflammatory bowel disease, asthma, and immune-mediated hemolytic anemia are managed with corticosteroids based on mechanistic rationale and accumulated clinical observation, but randomized controlled trials in cats are scarce. The clinician should therefore apply corticosteroid therapy with explicit outcome criteria, document response objectively, and be prepared to revise the treatment plan when expected benefits do not materialize.

## Corticosteroid Responsiveness Across Disease States

Not all inflammatory conditions respond equally to corticosteroids. In human asthma, for example, type 2-high inflammation driven by IL-4, IL-5, and IL-13 is generally corticosteroid responsive, whereas type 2-low asthma with neutrophilic inflammation is associated with corticosteroid unresponsiveness [Hammad and Lambrecht, the basic immunology of asthma](https://pubmed.ncbi.nlm.nih.gov/33711259/). A parallel distinction likely operates in feline diseases. Eosinophilic conditions such as feline asthma, eosinophilic granuloma complex, and eosinophilic enteritis tend to respond well to corticosteroids. Neutrophilic or mixed inflammatory patterns may respond less predictably.

This differential responsiveness argues for diagnostic confirmation before committing a cat to long-term corticosteroid therapy. Cytology, histopathology, and imaging that characterize the inflammatory infiltrate provide information that predicts therapeutic response. A cat with suspected inflammatory bowel disease should ideally have intestinal biopsies before starting corticosteroids, both to confirm the diagnosis and to exclude neoplasia such as small cell lymphoma, which may require different therapy. When biopsy is not feasible, a therapeutic trial with explicit response criteria and a defined reassessment point is acceptable, provided the owner understands the diagnostic uncertainty.

## Regulatory and Stewardship Context

Corticosteroid use in cats falls under the same regulatory framework as other veterinary pharmaceuticals. The FDA Center for Veterinary Medicine oversees approval, labeling, and adverse event reporting for animal drugs in the United States [FDA Center for Veterinary Medicine, animal drug information](https://www.fda.gov/animal-veterinary). Most corticosteroid products used in feline practice are approved for dogs or for multiple species, making their use in cats extralabel. Extralabel use requires a valid veterinarian-client-patient relationship, and the prescribing veterinarian assumes responsibility for appropriate dosing and monitoring.

Corticosteroids are not antimicrobials, and antimicrobial stewardship principles do not directly govern their use. However, the broader framework of judicious drug use applies. The AVMA emphasizes stewardship as a professional obligation that extends to all therapeutic classes [AVMA antimicrobial use and stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). For corticosteroids, stewardship means using the lowest effective dose for the shortest necessary duration, documenting the indication, and avoiding use when alternative therapies with fewer long-term risks are available.

## Pretreatment Assessment and Case Selection

The decision to initiate corticosteroid therapy in a cat begins with a structured assessment that confirms both the indication and the absence of contraindications. A minimum database should include a complete blood count, serum biochemistry profile, urinalysis with culture when indicated, and blood pressure measurement. Feline patients frequently mask systemic disease, and a cat presenting with dermatologic signs may have concurrent diabetes mellitus, chronic kidney disease, or hyperthyroidism that materially alters the risk-benefit calculation.

Diagnostic confirmation precedes therapy in all but the most life-threatening presentations. Cytology, histopathology, or antigen testing should establish the diagnosis before corticosteroids are administered, because glucocorticoid administration can obscure the diagnostic features of neoplasia and infectious disease. For suspected immune-mediated disease, baseline testing also provides the comparator needed to judge therapeutic response and detect drug-induced changes in later monitoring.

Absolute contraindications include systemic fungal infection, uncontrolled bacterial infection, and known hypersensitivity to the formulation. Relative contraindications include diabetes mellitus, chronic kidney disease, congestive heart failure, and a history of corticosteroid-associated adverse effects. In these patients, alternative immunomodulatory agents should be considered first, and if corticosteroids are unavoidable, the lowest effective dose with the shortest duration should be used with intensified monitoring.

## Corticosteroid Selection and Feline Dosing Considerations

Cats differ from dogs in their pharmacokinetic handling of corticosteroids, and these differences influence drug selection. Prednisolone is preferred over prednisone in cats because hepatic conversion of prednisone to the active metabolite prednisolone is less efficient in this species. Oral absorption of prednisone in cats is variable, and clinical response to prednisone may be inferior. Current formulary references should be consulted for specific dose ranges, as published recommendations vary by indication and formulation.

The table below summarizes commonly used corticosteroids in feline practice with their relative potencies and practical considerations. Doses are expressed as relative ranges instead of absolute values because the approved label and current formulary must guide prescribing.

| Drug | Relative anti-inflammatory potency | Relative mineralocorticoid potency | Feline-specific considerations |
|------|-----------------------------------|-----------------------------------|-------------------------------|
| Hydrocortisone | 1 | 1 | Rarely used systemically, mineralocorticoid effects limit utility |
| Prednisolone | 4 | 0.8 | Preferred oral glucocorticoid in cats, use the alcohol form, not the prodrug |
| Methylprednisolone | 5 | 0.5 | Intermediate duration, useful when a slightly longer effect is desired |
| Triamcinolone | 5 | 0 | Depot formulations available, duration of suppression is prolonged |
| Dexamethasone | 25 to 30 | 0 | High potency, useful for acute life-threatening conditions, longer suppression |
| Betamethasone | 25 to 40 | 0 | Similar to dexamethasone, limited systemic use in cats |

The choice between short-acting and depot formulations deserves particular attention. Repository forms such as methylprednisolone acetate provide sustained release but cannot be withdrawn quickly if adverse effects develop. A cat that develops diabetes mellitus or congestive heart failure while under the influence of a depot corticosteroid remains exposed for weeks. For initial therapy, short-acting oral preparations allow dose titration and rapid discontinuation. Depot formulations are best reserved for situations where owner compliance is unreliable or where the disease process is known to require prolonged suppression.

## Monitoring Parameters and Frequency

Monitoring serves three purposes: confirming therapeutic efficacy, detecting dose-dependent adverse effects, and identifying disease relapse during taper. The frequency and intensity of monitoring depend on the duration of therapy and the cat's baseline status.

For short courses of less than two weeks, monitoring is primarily clinical. Body weight, appetite, water intake, and urine output should be assessed at each recheck. Blood pressure measurement is warranted if the cat is geriatric, has pre-existing renal disease, or receives a potent glucocorticoid such as dexamethasone.

For maintenance therapy exceeding four weeks, laboratory monitoring should be scheduled at one month, then every three to six months. The table below outlines the monitoring parameters, the abnormality each detects, and the action triggered by an abnormal result.

| Parameter | Abnormality detected | Action on abnormal result |
|-----------|---------------------|---------------------------|
| Blood glucose and fructosamine | Diabetes mellitus or worsening glycemic control | Taper or discontinue corticosteroid, initiate insulin if indicated |
| Blood pressure | Systemic hypertension | Taper dose, initiate antihypertensive therapy if persistent |
| Urinalysis with culture | Urinary tract infection, glucosuria | Treat infection, reassess steroid necessity |
| Serum creatinine and SDMA | Kidney injury or progression of CKD | Taper dose, address hydration and renal support |
| Body weight and muscle condition score | Iatrogenic hyperadrenocorticism, protein catabolism | Reduce dose, consider alternate-day therapy |
| Alanine aminotransferase and alkaline phosphatase | Hepatopathy | Rule out other causes, monitor trend |
| Fecal examination | Recrudescence of parasitic disease | Treat parasitism, reassess immunosuppression |

Cats receiving immunosuppressive doses require more frequent monitoring than those on anti-inflammatory doses. The distinction between these dose ranges is also quantitative. Immunosuppressive therapy carries a higher risk of opportunistic infection and requires vigilance for signs of sepsis, which in cats may present as lethargy, hypothermia, and anorexia instead of fever.

## Troubleshooting Adverse Effects

The most common adverse effects of corticosteroid therapy in cats are polydipsia, polyuria, polyphagia, and weight gain. These effects are dose dependent and typically reversible with dose reduction. When they appear, the clinician should first confirm that the dose is the lowest effective dose, then consider alternate-day administration if the disease permits.

Diabetes mellitus is the most consequential metabolic adverse effect. Cats are predisposed to corticosteroid-induced insulin resistance, and overt diabetes may develop within days to weeks of initiating therapy. Fructosamine provides a two to three week average of glycemic control and is useful for distinguishing transient steroid-induced hyperglycemia from persistent diabetes. If diabetes develops, the corticosteroid should be tapered to the lowest dose that controls the primary disease, and insulin therapy initiated according to current guidelines.

Iatrogenic hyperadrenocorticism presents with alopecia, thin skin, muscle wasting, and a pot-bellied appearance. This syndrome develops after months of therapy and requires gradual tapering of the corticosteroid to allow recovery of the hypothalamic-pituitary-adrenal axis. Abrupt withdrawal after prolonged therapy can precipitate hypoadrenocortical crisis, presenting as weakness, collapse, and gastrointestinal signs.

Urinary tract infection is a recognized complication of immunosuppressive therapy. Cats may develop bacteriuria without overt clinical signs, and routine urinalysis with culture is recommended during maintenance therapy. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains adverse event reporting systems that clinicians should use when unexpected reactions occur, particularly with compounded or extralabel preparations.

Gastrointestinal ulceration is less common in cats than in dogs receiving corticosteroids, but the risk increases when corticosteroids are combined with nonsteroidal anti-inflammatory drugs. This combination should be avoided unless the clinical situation demands it, and gastroprotectant therapy should be considered when concurrent use is unavoidable.

## Documentation and Communication

Medical records should document the indication for therapy, the drug and formulation selected, the starting dose, the planned taper schedule, and the monitoring schedule. Each recheck should record the clinical response, any adverse effects observed, body weight, blood pressure, and laboratory results. This documentation supports dose adjustments and provides the basis for client communication about the expected course of therapy.

Client communication should address the expected time to response, the duration of therapy, and the specific adverse effects to monitor at home. Owners should be instructed not to discontinue the medication abruptly and to report increased thirst, increased urination, or changes in appetite. Written instructions reduce the risk of dosing errors, particularly when tapering schedules are complex.

The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific pharmacology and monitoring guidance that can supplement clinical decision-making. Professional judgment remains the final arbiter, particularly in cats with multiple comorbidities where the interaction between corticosteroid effects and concurrent disease is unpredictable.

## Recognized Complications and Early Detection

The most consequential corticosteroid complications in cats differ from those emphasized in canine practice. Iatrogenic hyperadrenocorticism, steroid hepatopathy, diabetes mellitus, congestive heart failure, and opportunistic infection dominate the clinical risk profile. Each has a detectable preclinical phase.

Iatrogenic hyperadrenocorticism develops insidiously with chronic therapy. Early signs include polyuria, polydipsia, polyphagia, and a dull, unkempt haircoat. The discriminating finding is failure of clinical improvement despite adequate dosing, which should prompt a cortisol suppression test instead of a dose increase. Cats receiving long-acting injectable formulations are disproportionately represented because the duration of suppression exceeds the visible anti-inflammatory effect.

Steroid hepatopathy in cats is characterized by vacuolar change and increased liver enzyme activity, particularly alkaline phosphatase. The isoenzyme profile differs from dogs, and the magnitude of ALP elevation is often modest. Serial biochemistry every 8 to 12 weeks during maintenance therapy detects progression before overt hepatic dysfunction appears.

Diabetes mellitus is the most clinically significant metabolic complication. Cats have a high density of glucocorticoid receptors on hepatocytes, and corticosteroid-induced insulin resistance can unmask latent disease rapidly. Routine urinalysis for glucosuria at each recheck, with blood glucose measurement when glucosuria appears, identifies the transition early. Once persistent hyperglycemia develops, the corticosteroid dose must be reduced or discontinued if the underlying disease permits.

Congestive heart failure is a recognized risk in cats with subclinical cardiomyopathy. The sodium-retaining effects of mineralocorticoid activity, combined with increased vascular volume, can precipitate pulmonary edema. Thoracic auscultation for a gallop rhythm or murmur, combined with baseline echocardiography in older cats before initiating therapy, reduces this risk. The sodium pump regulatory mechanisms affected by corticosteroids are tissue specific, and the cardiac response varies between individuals [mechanisms of sodium pump regulation](https://pubmed.ncbi.nlm.nih.gov/10942705/).

Opportunistic infection, particularly upper respiratory viral recrudescence and dermatophytosis, appears during immunosuppressive dosing. Owners should be instructed to report new skin lesions, nasal discharge, or lethargy between scheduled visits.

## Common Errors and Corrective Actions

The most frequent error is underdosing oral prednisolone in cats. Hepatic 11-beta-hydroxysteroid dehydrogenase converts prednisone to prednisolone inefficiently in some cats, and clinical response to prednisone is less reliable. Use prednisolone as the default oral glucocorticoid in feline practice.

A second error is prolonged use of long-acting injectable methylprednisolone acetate for chronic inflammatory disease. The duration of adrenal suppression is unpredictable, and dose titration is impossible once administered. Reserve depot formulations for situations where oral administration is not feasible.

A third error is abrupt discontinuation after prolonged therapy. Adrenal suppression develops with courses exceeding three to four weeks, and rapid withdrawal can precipitate hypoadrenocortical crisis. Tapering schedules should be individualised and documented in the medical record.

A fourth error is failure to reassess the diagnosis when response is poor. Corticosteroid responsiveness varies by disease and individual, and the inverted-U dose response means that both underdosing and overdosing can produce suboptimal outcomes [acute effects of corticosteroids on cognition](https://pubmed.ncbi.nlm.nih.gov/9233540/). If a cat fails to improve on an adequate dose, reconsider the diagnosis before escalating therapy.

## Limitations of Current Evidence

The feline corticosteroid evidence base is thinner than the canine literature. Most dosing recommendations derive from clinical experience, extrapolation from other species, and small case series instead of randomised controlled trials. The concordance between animal model results and clinical trial outcomes is imperfect, and this discordance is documented across multiple therapeutic areas [comparison of treatment effects between animal experiments and clinical trials](https://pubmed.ncbi.nlm.nih.gov/17175568/). Clinicians should therefore treat published dose ranges as starting points, not fixed rules.

Expert opinion differs on several points. The threshold for adding adjunctive immunosuppressants in feline inflammatory bowel disease remains contested. Some specialists advocate early combination therapy to spare glucocorticoid exposure, while others prefer sequential escalation. The optimal monitoring interval for cats on long-term therapy is similarly unsettled, with recommendations ranging from monthly to quarterly biochemistry.

The role of topical ocular corticosteroids in cats with eosinophilic keratitis is well established, but the systemic absorption and long-term corneal effects are less well characterized. Specialist opinion favours the lowest effective frequency and duration.

## Referral and Escalation Criteria

Referral to a specialist is warranted when the diagnosis is uncertain, when a cat fails to respond to an adequate trial of therapy, when glucocorticoid-sparing agents are required, or when complications threaten to outweigh benefits. Specific scenarios include suspected insulinoma or other paraneoplastic disease, atypical hyperadrenocorticism, and inflammatory bowel disease that requires endoscopic biopsy for confirmation.

Laboratory involvement is indicated when monitoring reveals unexplained cytopenias, progressive liver enzyme elevation, or persistent hyperglycemia. A veterinary clinical pathologist can assist with interpretation of adrenal function tests and differentiation of steroid hepatopathy from other hepatic disease.

Regulatory reporting obligations arise when an adverse drug event occurs with an approved product. The FDA Center for Veterinary Medicine maintains adverse event reporting pathways for animal drugs, and veterinarians should report suspected adverse reactions even when causality is uncertain [FDA Center for Veterinary Medicine animal drug information](https://www.fda.gov/animal-veterinary). Professional practice resources from the AVMA provide additional guidance on documentation and reporting expectations [AVMA practice resources](https://www.avma.org/resources-tools).

## Troubleshooting Table

| Observation | Likely Cause | Discriminating Check |
|---|---|---|
| Poor clinical response at standard dose | Underdosing, malabsorption, or wrong diagnosis | Verify prednisolone not prednisone, reassess diagnosis, consider serum drug monitoring where available |
| Polyuria and polydipsia after dose increase | Iatrogenic hyperadrenocorticism or diabetes mellitus | Urinalysis for glucosuria, paired blood glucose and cortisol measurement |
| Progressive ALP elevation on maintenance therapy | Steroid hepatopathy | Serial biochemistry, consider hepatic ultrasound if enzymes continue to rise |
| Acute tachypnoea or dyspnoea | Precipitated congestive heart failure | Thoracic radiographs, echocardiography in suspected subclinical cardiomyopathy |
| New skin lesions or nasal discharge | Opportunistic infection | Cytology, fungal culture, or PCR as indicated |
| Vomiting or diarrhea after depot injection | Gastrointestinal adverse effect or pancreatitis | Biochemistry including lipase, abdominal ultrasound if severe |

## Frequently Asked Questions

### How do I adjust corticosteroid therapy when financial constraints limit diagnostic testing?

When owners cannot fund advanced diagnostics, treatment must proceed on a probability basis while managing risk. A therapeutic trial of a glucocorticoid is reasonable for suspected inflammatory bowel disease, asthma, or eosinophilic conditions after baseline blood work, fecal examination, and imaging exclude obvious infectious or neoplastic causes. Document the presumptive diagnosis, the planned response criteria, and the timeline for reassessment. Recheck visits are not optional, schedule them before starting therapy. If response is incomplete or transient, revisit the diagnosis instead of escalating the dose. The FDA Center for Veterinary Medicine provides regulatory guidance on approved drug use and adverse event reporting that supports this structured approach to therapy [FDA CVM animal drug information](https://www.fda.gov/animal-veterinary).

### What monitoring is feasible when a cat cannot return for frequent rechecks?

Remote monitoring can substitute for some in-person visits but not all. Train owners to track body weight weekly, appetite, water intake, litter box output, and clinical signs using a simple diary. Phone or video consultations can assess demeanor and respiratory effort. Laboratory monitoring, however, requires clinic visits. Prioritize a glucose and urine glucose check within 7 to 14 days of starting therapy, then a complete blood count and biochemistry panel at 4 to 6 weeks. If travel is difficult, coordinate with a local veterinary clinic for sample collection and send results electronically. The MSD Veterinary Manual offers species-specific guidance on monitoring parameters and expected adverse effects that supports this tiered approach [MSD Veterinary Manual professional reference](https://www.msdvetmanual.com/).

### How does corticosteroid use in cats differ from dogs in practical decision making?

Cats metabolize glucocorticoids more slowly, show greater resistance to steroid-induced polyuria and polydipsia, and are more prone to certain adverse effects such as steroid hepatopathy and skin fragility. They also require lower relative doses for immunosuppression than dogs. The inverted-U dose response described in corticosteroid research applies across species, but the optimal range differs for cats [acute corticosteroid effects on cognition and dose response](https://pubmed.ncbi.nlm.nih.gov/9233540/). Cats often tolerate alternate-day protocols poorly because of their longer drug half-life, so daily dosing with gradual taper is usually preferred. When switching from injectable to oral therapy, account for the prolonged duration of action of repository formulations. Consult a current veterinary formulary for species-specific dose ranges instead of extrapolating from canine protocols.

### What records should I maintain for a cat on long-term corticosteroid therapy?

Maintain a treatment log that includes the indication, drug and formulation, starting dose, taper schedule, and every dose adjustment with the reason. Record baseline and serial body weights, laboratory results, and blood pressure measurements. Document owner-reported adverse effects and the date each was discussed. Note the planned duration of therapy and the criteria for discontinuation. If the cat receives concurrent medications, record potential interactions, particularly nonsteroidal anti-inflammatory drugs and insulin. The AVMA practice resources emphasize that thorough medical records support continuity of care and defensible clinical decisions [AVMA practice resources](https://www.avma.org/resources-tools). For cats that may enter a household with children or immunocompromised individuals, document the discussion of handling precautions.

### How should I respond when a cat fails to improve on an adequate corticosteroid trial?

First verify the owner actually administered the medication. Cats are notoriously difficult to pill, and hidden doses are common. Confirm the formulation was not expired or improperly stored. Then reassess the diagnosis. Lack of response to corticosteroids is a recognized feature of certain disease endotypes, as described in asthma research where type 2-low inflammation responds poorly to steroid therapy [basic immunology of asthma and steroid responsiveness](https://pubmed.ncbi.nlm.nih.gov/33711259/). Consider concurrent infection, neoplasia, or a non-inflammatory cause. Review the dose: cats may require higher relative doses for immunosuppression. If the dose is adequate and compliance confirmed, taper and discontinue the drug while pursuing further diagnostics. Do not simply increase the dose indefinitely without a defined endpoint.

### When should I refer a cat on corticosteroid therapy to a specialist?

Refer when the diagnosis is uncertain after initial investigation, when the cat requires prolonged high-dose therapy, or when adverse effects become difficult to manage. Specific triggers include suspected steroid-induced diabetes mellitus that does not resolve with dose reduction, cutaneous fragility, severe steroid hepatopathy, or recurrent infections. Referral is also appropriate when the owner requests a second opinion or when the cat fails to respond to an adequate trial, as this suggests an atypical disease process. The AVMA provides guidance on professional collaboration and referral pathways that support timely specialist consultation [AVMA professional practice guidance](https://www.avma.org/resources-tools). Prepare a complete summary of prior treatments, doses, response, and laboratory results before referral.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Mechanisms of sodium pump regulation.](https://pubmed.ncbi.nlm.nih.gov/10942705/). 2000.
- [The acute effects of corticosteroids on cognition: integration of animal and human model studies.](https://pubmed.ncbi.nlm.nih.gov/9233540/). 1997.
- [Comparison of treatment effects between animal experiments and clinical trials: systematic review.](https://pubmed.ncbi.nlm.nih.gov/17175568/). 2007.
- [Alcoholic liver disease: pathogenesis and new therapeutic targets.](https://pubmed.ncbi.nlm.nih.gov/21920463/). 2011.
- [The basic immunology of asthma.](https://pubmed.ncbi.nlm.nih.gov/33711259/). 2021.
- [Alcoholic liver disease: mechanisms of injury and targeted treatment.](https://pubmed.ncbi.nlm.nih.gov/25782093/). 2015.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Corticosteroid Therapy in Canine Atopic Dermatitis: Dosing and Monitoring](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-canine-atopic-dermatitis-dosing-monitoring)
- [Corticosteroid Therapy in Canine Inflammatory Diseases: Balancing Efficacy and Safety](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-canine-inflammatory-diseases-balancing-efficacy-safety)
- [Corticosteroid Therapy in Feline Inflammatory Bowel Disease: Dosing and Monitoring](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-feline-ibd)
- [Corticosteroid Use in Canine Dermatology: A Practical Approach](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-use-canine-dermatology-practical-approach)
- [Corticosteroid Therapy in Canine Immune-Mediated Hemolytic Anemia: Balancing Risks and Benefits](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-canine-imha)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.